Name	Provider	Purpose	Expiry	Type
show_cookie_notice	About Cookies			cookie type

Revolutionizing Genomics: How MGI Spurs Healthy Market Competition, Insights from GNOMIX's Chief Scientist

16.04.2023

Offline

GNOMIX: A Leader in Genetic Consulting Services

Established in 2020, GNOMIX has quickly emerged as a trusted provider of genetic consulting services. The laboratory has been accredited by the National Association of Testing Agencies of Australia (NATA) and meets the ISO/IEC 17025 laboratory testing standards. GNOMIX prides itself on offering tailored solutions to niche markets, catering to the specific needs of its diverse customer base.

Dr. Scott Grist, the chief scientist of GNOMIX, emphasizes the laboratory's commitment to customer satisfaction. He states, "Our goal is not to compete with mainstream pathology laboratories but to provide customized and timely response services. The arrival of MGI has promoted healthy competition in the market, enabling us to offer more possibilities for the development of the genomics industry.

The Impact of MGI in the Genomics Industry

MGI, a renowned manufacturer of gene sequencing technology, has played a crucial role in fostering healthy competition in the genomics industry. GNOMIX has embraced MGI's state-of-the-art equipment, including the MGISEQ-200 gene sequencer and the MGISP-100 automatic sample preparation system.

The MGISEQ-200, also known as the DNBSEQ-G50 overseas, is a compact and powerful gene sequencer that strikes a perfect balance between speed and price. It supports high and low throughput slides, making it suitable for a wide range of applications, from low-depth whole genome sequencing to targeted capture/multiplex sequencing, RNA sequencing, and more.

The MGISP-100 automated sample preparation system complements the MGISEQ-200, catering to the needs of small and medium-sized throughput. By automating time-consuming procedures and enhancing overall work efficiency, the system enables GNOMIX to provide faster and more convenient sequencing services to its customers.

Advancing Accessibility and Inclusivity in Genomics

Dr. Grist believes that the development of the genomics industry should not solely rely on mainstream market players. While they may struggle to provide customized services promptly, GNOMIX, in collaboration with MGI, aims to make genomics services more accessible and inclusive. The advent of MGI has introduced healthy competition, driving the industry towards wider adoption of gene sequencing technology.

Expanding GNOMIX's Customer Base and Capacity

During the COVID-19 pandemic, GNOMIX expanded its customer base, not only in the local market but also internationally. By leveraging the MGISEQ-200's throughput capabilities for small-scale experiments, GNOMIX met the demands of primary experiments and continued to grow its business. Dr. Grist expressed the laboratory's consideration of introducing the MGISEQ-2000 gene sequencer with even higher throughput to further expand its operations.

Furthermore, GNOMIX has supported numerous innovative projects, including clinical trials, primary research, high-impact publications, and large-scale commercial ventures. The laboratory's collaboration with MGI has allowed it to rapidly scale up its capacity and meet the growing demand for genetic consulting services.

GNOMIX, as a leading molecular genetics laboratory in Australia, has benefited greatly from its collaboration with MGI. The arrival of MGI has promoted healthy competition in the genomics market, empowering GNOMIX to provide customized and timely genetic consulting services. By embracing MGI's advanced gene sequencing technology, including the MGISEQ-200 and MGISP-100, GNOMIX has enhanced its throughput capabilities and expanded its customer base.

The partnership between MGI and GNOMIX demonstrates their shared vision of advancing the genomics industry. Through cooperation, they aim to contribute to the development of precision medicine in Australia and globally. As the industry continues to evolve, MGI's commitment to innovation and GNOMIX's dedication to excellence position them as key players in shaping the future of molecular genetics.

About MGI

MGI Tech Co., Ltd. (MGI) is committed to building core tools and technology to lead life science through intelligent innovation. Based on its proprietary technology, MGI focuses on research & development, production and sales of sequencing instruments***, reagents***, and related products to support life science research, agriculture, precision medicine and healthcare. MGI's mission is to develop and promote advanced life science tools for future healthcare. As of December 2021, MGI has a footprint that spans across more than 80 countries and regions, serves over 1,300 international users and employs more than 2,050 professionals globally, around 35% of which are R&D personnel. For more information, please visit MGI website or connect on Twitter, LinkedIn or YouTube.

About Cookies

Revolutionizing Genomics: How MGI Spurs Healthy Market Competition, Insights from GNOMIX's Chief Scientist

The Impact of MGI in the Genomics Industry

Advancing Accessibility and Inclusivity in Genomics

Expanding GNOMIX's Customer Base and Capacity

About MGI

More news

As a new Core Lab under the Million Microbiomes from Humans Project, MGI empowers INRAE MetaGenoPolis in“Le microbiote français - Le French Gut”project to Propel Metagenomics Research.

Accelerated and Enhanced Virus Sequencing Achieved at Latvian Biomedical Research Center using the MGI Sequencing Platform

User Voice | Turkish Genetic Disease Diagnosis Center: MGI’s sequencing technology and platform can provide us with more stable and accurate data results

Thank you for subscribing to our newsletter!

Please check your email and verify your email address.

Get our newsletter to be the first to learn about product updates and new opportunities brought to the industry by our innovation.

Thank you for subscribing
to our newsletter!